Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2009

View Archived Issues

Novel Flt3 inhibitors in early development at Biovitrum for proliferative disorders

Arpida and Evolva plan merger

Genfit progresses AD-Inov program in Alzheimer's disease

CytRx receives FDA letter regarding phase IIb arimoclomol trial in ALS

Affymax provides update for phase III Hematide program in chronic renal failure

Inviragen receives grant to support dengue vaccine development

QuatRx reports results of second pivotal phase III study of Ophena

NuPathe reports data from pivotal phase III Zelrix trial in acute migraine

Theravance and Astellas obtain FDA approval of Vibativ

Centocor Ortho Biotech receives two FDA Complete Response letters for Doxil combinations

Enrollment completed in phase III VEGF Trap-Eye studies in wet AMD

Cellerix's Cx-601 obtains EMEA orphan medicinal product status

StemCells to initiate neural stem cell trial in myelination disorder

GenSpera receives FDA approval to commence phase I G-202 trial in cancer

Atomoxetine improves symptoms of Parkinson's disease

LegoChem Biosciences describes novel cyclic amidrazone antibiotics

Details of phase II study with OP-145 in otitis media presented

Novel aminoglycoside ACHN-490 shows potent preclinical activity and clinical safety

Fatty acid synthase inhibitor UCM-Gi028 developed for anti-HER resistant cancer therapy

Long-term effects, cardiac safety and cognitive improvement assessed with fampridine-SR

Cephalon and Pharmacopeia describe histamine H3 receptor antagonists under development

New antibacterial compounds discovered by scientists at Princeton University

NovaBay and Galderma commence study of NVC-422 for impetigo

PTC Therapeutics initiates registration-directed phase III trial of ataluren in cystic fibrosis

Celldex Therapeutics doses first patient in phase I/II cancer vaccine trial

Verona reports final results of phase I/IIa RPL-554 trial in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...